Elite Pharmaceuticals Inc
ELTP- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001053369
In the last 90 days, Elite Pharmaceuticals Inc insiders filed 2 open-market purchases and 0 sales; 1 institution reported holding it in 13F filings for Q2 2026, worth $365 in total; no superinvestor holds it.
Key figures
- Market capNo recent closing price
- –
- Insider buysLast 90 days, $34.6K in total
- 2
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, 0 vs. previous quarter
- 1
- 13F valueReported value at the end of Q2 2026
- $365
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2026
- $148.9M
- +77.1% year over year
- Net income, FY2026
- $44.9M
- No comparable prior period
- Free cash flow, FY2026
- $22.8M
- +291.4% year over year
- Revenue, Q1 FY2027
- $32.4M
- −19.5% year over year
Revenue flow, FY2026
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 2.99M
- Shares sold short
- Change
- −42.7K
- −1.4% vs. previous
- Days to cover
- 2.76
- At average daily volume
Superinvestors holding ELTP, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding ELTP at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Elite Pharmaceuticals Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 19, 2026 (view filing)6:05 AM ET | Oct 9 | 10 daysLate | Dash Barry HDirector | PPurchase | +100.0K | $0.2598 | +$26.0K | +3.1%3.37M after | |
| Sep 10, 2026 (view filing)1:29 PM ET | Aug 19 | 22 daysLate | Dash Barry HDirector | PPurchase | +30.0K | $0.287 | +$8.61K | +0.9%3.27M after | |
| Oct 3, 2025 (view filing) | Oct 2 | 1 day | Plassche DouglasEVP Operations | SSale | −800.0K | $0.62 | −$496.0K | −18.6%3.50M after | |
| Aug 26, 2025 (view filing)5:17 PM ET | Aug 22 | 4 days | Elite Pharmaceuticals IncEVP Operations | SSale | −500.0K | $0.5243 | −$262.1K | −21.7%1.80M after | |
| Jul 25, 2025 (view filing) | Jul 10 | 15 daysLate | Kirkov KirkoChief Commercial Officer | PPurchase | +16.4K | $0.59 | +$9.66K | New position16.4K after | |
| Jul 10, 2025 (view filing) | Jul 8 | 2 days | Plassche DouglasEVP Operations | SSaleStock Options (right to buy) | −200.0K | $0.58 | −$116.0K | −8.0%2.30M after | |
| Oct 28, 2024 (view filing)5:23 PM ET | Oct 23-24 | 5 daysLate | Plassche DouglasSVP of Operations | SSale | −1.13M | $0.4959 | −$562.3K | −100.0%0 after | 2 lots |
Top 10 13F holders, Q2 2026
See all 1 holdersThe largest institutional positions in Elite Pharmaceuticals Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wall Street Access Asset Management, LLC | 1,000 | $365 | 0.00% | +500+100.0% | Added |